Held by 3 specialist biotech funds
High Convergence# Signal Note: Perceptive Initiates RGEN Position Perceptive Advisors' $51.7M entry into Repligen signals conviction in the biotech's core business—the company is a leading supplier of filtration and chromatography systems for biopharmaceutical manufacturing, not a clinical-stage drug developer.
AI analyst context — unlock full analysis
# RTW Investments Initiates $174M RGEN Position Wong's significant new stake in Repligen signals confidence in the company's bioprocess solutions portfolio, which benefits from sustained demand in cell and gene therapy manufacturing—a secular tailwind as more advanced therapies move toward commercialization. The entry size (1.06M shares, ~3.4% of outstanding) suggests conviction in RGEN's recurring revenue model and margin expansion potential, particularly as its chromatography and filtration platforms become standard manufacturing infrastructure across the biopharma industry.
+ 1 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial